Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain-Reference-Cited by-同舟云学术

Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain

Published:2014-09-24 Issue:3 Volume:40 Page:650-657
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol

Author:

Fowler Joanna S,Logan Jean,Volkow Nora D,Shumay Elena,McCall-Perez Fred,Jayne Millard,Wang Gene-Jack,Alexoff David L,Apelskog-Torres Karen,Hubbard Barbara,Carter Pauline,King Payton,Fahn Stanley,Gilmor Michelle,Telang Frank,Shea Colleen,Xu Youwen,Muench Lisa

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/npp2014214.pdf

Reference45 articles.

1. Alexoff DL, Shea C, Fowler JS, King P, Gatley SJ, Schlyer DJ et al (1995). Plasma input function determination for PET using a commercial laboratory robot. Nucl Med Biol 22: 893–904.

2. Amsterdam JD (2003). A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 64: 208–214.

3. Alia-Klein N, Goldstein RZ, Kriplani A, Logan J, Tomasi D, Williams B et al (2008). Brain monoamine oxidase A activity predicts trait aggression. J Neurosci 28: 5099–5104.

4. Azzaro AJ, Vandenberg CM, Blob LF, Kemper EM, Sharoky M, Oren DA et al (2006). Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. J Clin Pharmacol 46: 933–944.

5. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C (2007). Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol 47: 1256–1267.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoamine oxidase and neurodegeneration: Mechanisms, inhibitors and natural compounds for therapeutic intervention;Neurochemistry International;2024-10

2. An overview of the role of monoamine oxidase-B in Parkinson’s disease: implications for neurodegeneration and therapy;Exploration of Neuroprotective Therapy;2024-07-14

3. Chalcones with N‐Methylpiperazine Moiety: Synthesis, Monoamine Oxidase Inhibition, Neuroprotective Effect and Computer Simulation Study;ChemistrySelect;2024-04-09

4. Novel 6-hydroxybenzothiazol-2-carboxamides as potent and selective monoamine oxidase B inhibitors endowed with neuroprotective activity;European Journal of Medicinal Chemistry;2024-04

5. Metabolic bioactivation of antidepressants: advance and underlying hepatotoxicity;Drug Metabolism Reviews;2024-02-20